GlassScriptPhysician profile
Majid Yavari
NPI 1487264677
$7,840.83
in general payments reported to CMS, 2019-2025
23 companies · $3,339 in 2025
The $3,339 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.42 · 2022: $14.25 · 2023: $111 · 2024: $4,361 · 2025: $3,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $4,150 · Food and Beverage: $3,566 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $4,150.00 |
| Food and Beverage | $3,566.17 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,150.00 | 2024-2025 | Tacticath |
| Amgen INC. | $435.45 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $407.15 | 2022-2025 | Brilinta, Farxiga, Wainua |
| Abiomed | $339.46 | 2024-2025 | Impella |
| Boston Scientific Corporation | $318.14 | 2024-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $307.41 | 2024-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $306.84 | 2025 | Onpattro |
| Medtronic, INC. | $275.18 | 2025 | Micra, Corevalve Evolut R |
| Pfizer INC. | $214.79 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $210.79 | 2024-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $187.56 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.61 | 2024-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $100.66 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $97.02 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $85.02 | 2021-2024 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.39 | 2024-2025 | Jardiance |
| Edwards Lifesciences Corporation | $48.76 | 2025 | Sapien 3 Ultra Resilia |
| Bridgebio Pharma, INC. | $44.12 | 2025 | Attruby |
| United Therapeutics Corporation | $25.93 | 2025 | Tyvaso |
| Terumo Medical Corporation | $25.59 | 2025 | Tr Band, Angio-Seal |
| Novo Nordisk INC | $21.51 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $21.43 | 2024 | |
| Merck Sharp & Dohme LLC | $14.02 | 2024 | Dificid, Zerbaxa, Recarbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majid Yavari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.